PRESS CENTER
新聞中心
News
-
2025/03/07Mycenax and Sartorius Join Forces to Enhance Biopharmaceutical Manufacturing Solutions
-
2024/11/28Mycenax and Apexcella collaborate to Advance Commercialization of Allogeneic Natural Killer Cell Therapies to Benefiting More Patients
-
2024/10/17Opening Ceremony of Mycenax's New Automated Fill-Finish Line
-
2024/06/26MYCENAX and CHITOSE Join Forces to Forge a New Era of Cell Line Development
-
2024/01/24Merck Signs MoU with Mycenax Biotech to Drive Innovation in Bioprocessing Technology
-
2023/06/15Mycenax Biotech has signed an MOU with StemCyte to strengthen its one-stop service chain for allogeneic cell therapy
-
2023/06/01Construction Commencement of Mycenax Biotech's Cell Therapy Pilot Plant
-
2022/09/21Mycenax signs MoU with KriSan Biotech: Building ADC Industry Value Chain
-
2022/07/28JCR Pharmaceuticals invests in Mycenax Biotech, becomes largest shareholder
-
2022/05/30Mycenax re-elected Dr. Allen Y. Chao as independent director
- 1
- 2
- 3